Skip to main content

Research Repository

Advanced Search

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. (2021)
Journal Article
Mahil, S., Yates, M., Langan, S., Yiu, Z., Tsakok, T., Dand, N., …study groups, P. C. (2021). Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. British Journal of Dermatology, 185(1), https://doi.org/10.1111/bjd.19755

BACKGROUND: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatm... Read More about Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey..

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Journal Article
Yiu, Z., Mason, K., Hampton, P., Reynolds, N., Smith, C., Lunt, M., …Warren, R. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183(2), 294 - 302. https://doi.org/10.1111/bjd.18981

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.

OBJECTIVES: (i) To assess the relative drug survival of... Read More about Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)..

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. (2019)
Journal Article
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, A. (in press). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181(6), 1265 - 1271. https://doi.org/10.1111/bjd.17849

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are ass... Read More about A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis..

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. (2019)
Journal Article
Warren, R., Marsden, A., Tomenson, B., Mason, K., Soliman, M., Burden, A., …Smith, C. (in press). Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), 1069 - 1076. https://doi.org/10.1111/bjd.16776

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin... Read More about Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study..

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. (2018)
Journal Article
Mason, K. (2018). Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154(5), 581 - 588. https://doi.org/10.1001/jamadermatol.2018.0183

Importance: Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but... Read More about Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR..

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength (2017)
Journal Article
Thorneloe, R. J., Griffiths, C. E., Emsley, R., Ashcroft, D. M., Cordingley, L., Biologic Interventions Register, B. A. O. D., …Warren, R. (2018). Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 138(4), 785 - 794. https://doi.org/10.1016/j.jid.2017.11.015

Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed "real-world" levels of self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psychological and biomedical fac... Read More about Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists
Dataset
Marshall, M., Mason, K., Bailey, J., Heron, N., Achanca, F., Chen, Y., …Jordan, K. (2022). The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists. [Dataset]

Marshall M, Mason K, Bailey J, Heron N, Achana F, Chen Y, Edwards J, Frisher M, Huntley A, Mallen C, Mamas M, Png ME, Tatton S, White S, Jordan KP. MSKCOM: main Public Output: The impact of musculoskeletal conditions on outcomes of other illnesses: a... Read More about The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists.